The margin of the Schuldschein loan is linked to the achievement of sustainability targets from two areas that are core to Fresenius as a healthcare group: treatment quality and product safety.
Sara Hennicken, CFO of Fresenius: “Sustainability is becoming increasingly important in financing. We are taking this into account with our first sustainable Schuldschein loan. With this transaction, we are diversifying our investor base and further strengthening our liquidity.”
The high investor demand significantly exceeded the originally intended volume of 300 million euros. This made it possible to set the pricing for each tranche at the tight end of the marketing range. In total, more than 50 institutional investors from Europe and Asia participated in the transaction.
The proceeds from the Schuldschein loan will be used for general corporate purposes, including the refinancing of existing financial liabilities. Settlement is scheduled for May 30, 2023.
The transaction was arranged by DZ BANK AG, Landesbank Hessen-Thüringen Girozentrale and ING. ING has acted as Sustainability Structuring Advisor to this transaction.
Fresenius is a global healthcare group, providing products and services for dialysis, hospital and outpatient medical care. In 2022, Group revenue were €40.8 billion. On March 31, 2023, the Fresenius Group had 313,812 employees worldwide.
For more information visit the Company’s website at www.fresenius.com Follow us on social media: www.fresenius.com/socialmedia
Fresenius SE & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg
Telefon: +49 (6172) 608-2302
Telefax: +49 (6172) 608-2294
http://www.fresenius.de
Corporate Communications
Telefon: +49 (6172) 608-2115
Fax: +49 (6172) 608-2294
E-Mail: martin.kunze@fresenius.com